These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21575099)

  • 21. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
    Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
    Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.
    Prager W; Bee EK; Havermann I; Zschocke I
    Clin Interv Aging; 2013; 8():449-56. PubMed ID: 23650444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin type a for facial rejuvenation: treatment evolution and patient satisfaction.
    Sepehr A; Chauhan N; Alexander AJ; Adamson PA
    Aesthetic Plast Surg; 2010 Oct; 34(5):583-6. PubMed ID: 20383497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines.
    Beer KR; Boyd C; Patel RK; Bowen B; James SP; Brin MF
    J Drugs Dermatol; 2011 Jan; 10(1):39-44. PubMed ID: 21197522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
    Cohen JL; Dayan SH; Cox SE; Yalamanchili R; Tardie G
    Dermatol Surg; 2012 Sep; 38(9):1497-505. PubMed ID: 22621180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skin cooling provides minimal relief of patient discomfort during periocular botulinum toxin type A injection.
    Beer KR; Wilson F
    Dermatol Surg; 2011 Jun; 37(6):870-2. PubMed ID: 21605254
    [No Abstract]   [Full Text] [Related]  

  • 28. Pooled Subject-Reported Outcomes From 2 Phase 3 Studies of OnabotulinumtoxinA for Simultaneous Treatment of Forehead and Glabellar Lines.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Larsen KE; Varon S; Garcia JK
    Dermatol Surg; 2020 Jul; 46(7):950-957. PubMed ID: 31567611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of administering abobotulinumtoxinA through a single injection point when treating lateral periocular rhytides.
    Kiripolsky MG; Goldman MP
    J Cosmet Dermatol; 2011 Sep; 10(3):232-4. PubMed ID: 21896136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A.
    Carruthers J; Carruthers A
    Dermatol Surg; 2003 Aug; 29(8):802-9. PubMed ID: 12859378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A small study of the relationship between abobotulinum toxin A concentration and forehead wrinkle reduction.
    Abbasi NR; Durfee MA; Petrell K; Dover JS; Arndt KA
    Arch Dermatol; 2012 Jan; 148(1):119-21. PubMed ID: 22250248
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary: Revisiting the data: mild resting glabellar lines improve with onabotulinumtoxinA.
    Contreras ME; Cohen JL
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2172-4. PubMed ID: 21244567
    [No Abstract]   [Full Text] [Related]  

  • 33. RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
    Lee DH; Kang SM; Feneran A; Youn CS; Kim JK; Cho S; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e1-7. PubMed ID: 23030660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides.
    Carruthers A; Carruthers J; Cohen J
    Dermatol Surg; 2003 May; 29(5):461-7. PubMed ID: 12752512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?
    Kaufman-Janette J; Cox SE; Dayan S; Joseph J
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study.
    Won CH; Kim HK; Kim BJ; Kang H; Hong JP; Lee SY; Kim CS
    Int J Dermatol; 2015 Feb; 54(2):227-34. PubMed ID: 25311357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation.
    Carruthers A; Carruthers J; Monheit GD; Davis PG; Tardie G
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2121-34. PubMed ID: 21134044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Muscle atrophy beyond the clinical effect after a single dose of OnabotulinumtoxinA injected in the procerus muscle: a study with magnetic resonance imaging.
    Koerte IK; Schroeder AS; Fietzek UM; Borggraefe I; Kerscher M; Berweck S; Reiser M; Ertl-Wagner B; Heinen F
    Dermatol Surg; 2013 May; 39(5):761-5. PubMed ID: 23379599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the spread of three botulinum toxin type A preparations.
    Kerscher M; Roll S; Becker A; Wigger-Alberti W
    Arch Dermatol Res; 2012 Mar; 304(2):155-61. PubMed ID: 22002325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles.
    Carruthers A; Carruthers J; Fagien S; Lei X; Kolodziejczyk J; Brin MF
    Dermatol Surg; 2016 Sep; 42(9):1094-101. PubMed ID: 27427996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.